Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,820Revenue $M861Net Margin (%)-24.6Altman Z-Score9.9
Enterprise Value $M20,793EPS $-1.4Operating Margin %-20.6Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-25.5Higher ROA y-yY
Price/Book8.810-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsY
Price/Sales23.05-y EBITDA Growth Rate %--Current Ratio3.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-7.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-11.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M160ROIC % (ttm)-9.3Gross Margin Increase y-yN

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJoel Greenblatt 2015-06-30 Sold Out $112.05 - $140
($123.93)
$ 129.244%Sold Out0
BMRNJoel Greenblatt 2015-03-31 Buy $90.28 - $129.14
($105.95)
$ 129.2422%New holding4,195
BMRNJoel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19
($83.42)
$ 129.2455%Sold Out0
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 129.2496%New holding3,885
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 129.24107%Sold Out0
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 129.24129%Reduce 69.03%40,700
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 129.24183%Reduce 60.99%131,400
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 129.24259%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 129.24292%Add 300.00%300,000
BMRNGeorge Soros 2011-12-31 Reduce-0.05%$30.07 - $35.38
($32.81)
$ 129.24294%Reduce 57.14%75,000
BMRNGeorge Soros 2011-06-30 Add0.07%$24.93 - $28.455
($26.32)
$ 129.24391%Add 862.36%191,510
BMRNMeridian Funds 2011-03-31 Reduce-0.28%$23.46 - $28.29
($25.46)
$ 129.24408%Reduce 51.54%348,800
BMRNGeorge Soros 2011-03-31 Buy 0.01%$23.46 - $28.29
($25.46)
$ 129.24408%New holding19,900
BMRNGeorge Soros 2010-09-30 Sold Out -0.02%$18.24 - $23.09
($20.93)
$ 129.24517%Sold Out0
BMRNMeridian Funds 2010-03-31 Add0.13%$18.75 - $23.81
($20.92)
$ 129.24518%Add 20.83%795,900
BMRNGeorge Soros 2010-03-31 Add$18.75 - $23.81
($20.92)
$ 129.24518%Add 35.87%30,300
BMRNGeorge Soros 2009-12-31 Buy 0.01%$15.49 - $18.98
($17.17)
$ 129.24653%New holding22,300
BMRNMeridian Funds 2009-09-30 Buy 0.53%$13.86 - $18.33
($15.84)
$ 129.24716%New holding658,700
BMRNBill Gates 2009-06-30 Sold Out -0.02%$11.92 - $15.94
($13.79)
$ 129.24837%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIENAIME JEAN JACQUESCEO 2015-08-12Sell1,500$134.72-4.07view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-07-20Sell3,000$150-13.84view
BIENAIME JEAN JACQUESCEO 2015-07-07Sell1,500$139.07-7.07view
SPIEGELMAN DANIEL KEVP, CFO 2015-06-05Sell1,649$122.35.67view
FUCHS HENRY JEVP, Chief Medical Officer 2015-06-05Sell1,864$122.325.66view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-06-04Sell1,362$122.355.63view
SPIEGELMAN DANIEL KEVP, CFO 2015-06-01Sell5,523$124.733.62view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-06-01Sell377$123.764.43view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-05-26Sell1,625$126.552.13view
BIENAIME JEAN JACQUESCEO 2015-05-21Sell1,500$126.12.49view

Press Releases about BMRN :

Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talaz Aug 24 2015 
    biotech 2015 Aug 20 2015 
    biotech 2015 Aug 20 2015 
    J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 

    More From Other Websites
    BioMarin Launches kNOWyourDuchenne, Comprehensive Program for Patients With Duchenne Muscular... Sep 01 2015
    BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn... Aug 31 2015
    BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn... Aug 31 2015
    Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews Aug 27 2015
    The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure Aug 27 2015
    Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review Aug 26 2015
    Sarepta Upgraded On Promising Muscular-Dystrophy Drug Aug 26 2015
    Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data Aug 26 2015
    Sarepta gains after-hours as FDA accepts application for Duchenne drug approval Aug 25 2015
    Medivation to Gain Global Rights to BioMarin's Talazoparib Aug 25 2015
    BioMarin's Medivation Deal Boosts EPS Aug 25 2015
    Two Bay Area drug companies cut half-billion-dollar cancer drug deal Aug 24 2015
    Medivation Buying Breast-Cancer Drug From BioMarin Aug 24 2015
    Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
    Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
    BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 24 2015
    Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
    Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK